News

Quebec researcher receives $250,000 over three years to investigate gene-based research to treat ALS Toronto – The ALS Society of Canada (ALS Canada) and Brain Canada are dedicated to a shared mission to advance amyotrophic lateral sclerosis (ALS) research. Together,…

Implementation of the Ontario Provincial ALS Program is critical for addressing the urgent needs of Ontarians living with ALS and their families Toronto – Today, people living with amyotrophic lateral sclerosis (ALS) and their caregivers join the ALS Society of…

Today, The Toronto Star has published an op-ed from Tammy Moore, CEO of the ALS Society of Canada (ALS Canada), which recognizes that Ontario’s health framework isn’t designed to address the unique challenges of ALS – a devastating disease that…

Amyotrophic lateral sclerosis (ALS) is a complex disease with varying symptoms and severity for people affected. Due to its heterogeneity, diagnosing the disease can be challenging and finding effective treatments can also be difficult. CAPTURE (Comprehensive…

Funding for first two projects to total $200,000 Toronto – Amyotrophic lateral sclerosis (ALS) is a disease that can progress with startling swiftness. The ALS Society of Canada (ALS Canada) recognizes the need to move quickly in funding promising research…

In Canada, what the provincial health care systems provide does not always match the needs of people living with ALS. This statement rings true for Ontario, where the current ALS care and support landscape in the province presents people living…

Updated on: January 31, 2024 Pharmaceutical company Ferrer has announced topline results from the ADORE (ALS Deceleration with ORral Edaravone) clinical trial in ALS. The Phase 3 study, conducted in Europe, investigated the efficacy of an oral formulation of edaravone…

As we bid farewell to 2023, we want to take a moment to celebrate YOU. Your dedication throughout this month, and indeed the entire year, has been nothing short of inspirational. As a community, you have rallied together to show…